Moleculent, a Stockholm, Sweden-based provider a functional biology platform, raised $26M in Series A funding.
The round was co-led by ARCH Venture Partners and Eir Ventures with participation from existing investors.
The company intends to use the funds to expand operations and its R&D sector.
Led by CEO Olle Ericsson, Moleculent is developing a functional profiling platform that allows scientists to map cell-cell communication directly in clinical tissue, providing insights to accelerate the functional understanding of biology. By understanding how cells communicate, coordinate their actions, and adapt to their surroundings in human tissues, scientists will gain a clear picture of the cellular complexity in health and disease.
This novel approach allows scientists to see how healthy cells function and how diseased cells differ at a complex, networked level. A complete picture of the cell-cell communication in a tumor, for example, offers a practical understanding of the signaling pathways and molecular mechanisms involved in drug response.
Commenting on the news, Olle Ericsson said: “The Moleculent platform has been designed to allow scientists to uncover radical new insights into the cellular level of human biology and pathology. We are very happy to partner with ARCH Venture Partners and Eir Ventures to bring this enabling platform to the scientific community.”
FinSMEs
11/06/2024